EUVIMEDEUVIMED entdecken
Übersichtsarbeit

18 F-Labeled Somatostatin Analogs as PET Tracers for the Somatostatin Receptor: Ready for Clinical Use

Hannes Leupe, Stephen Ahenkorah, Jeroen Dekervel, Marcus Unterrainer, Eric Van Cutsem, Chris Verslype, Frederik Cleeren, Christophe M Deroose

Journal of Nuclear Medicine · 2023-06 · 64 (6) · 835-841

DOI: 10.2967/jnumed.123.265622 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 11.05.2023. Verfasst von Hannes Leupe und 7 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine, University Hospitals Leuven, and Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, University of Leuven,…. Hauptthemen laut MEDLINE: Somatostatin, Neuroendocrine Tumors. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Molecular imaging of the somatostatin receptor plays a key role in the clinical management of neuroendocrine tumors. PET imaging with somatostatin analogs (SSAs) labeled with 68Ga or 64Cu is currently the gold standard in clinical practice. However, widespread implementation of 68Ga imaging is often hampered by practical and economic issues related to 68Ge/68Ga generators. 18F offers several advantages to tackle these issues. Recent developments in radiochemistry have allowed a shift from 68Ga toward 18F labeling, leading to promising clinical translations of 18F-labeled SSAs, such as Gluc-Lys-[18F]FP-TOCA, [18F]F-FET-βAG-TOCA, [18F]AlF-NOTA-octreotide, [18F]SiTATE, and [18F]AlF-NOTA-JR11. This review gives an update of currently available clinical data regarding 18F-labeled SSA tracers and provides justification for the clinical application of this class of tracers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SomatostatinNeuroendocrine TumorsHumansReceptors, SomatostatinGallium RadioisotopesRadiopharmaceuticalsPositron-Emission Tomography

Stichwörter der Autor:innen

fluorine-18-labeled PET tracerneuroendocrineneuroendocrine tumorradiopharmaceuticalssomatostatin analoguesomatostatin receptor

Substanzen

SomatostatinReceptors, SomatostatinGallium RadioisotopesRadiopharmaceuticals

Autor:innen und Institutionen

  • Nuclear Medicine, University Hospitals Leuven, and Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, University of Leuven, Leuven, Belgium.
  • Radiopharmaceutical Research, Department of Pharmacy and Pharmacology, University of Leuven, Leuven, Belgium.
  • Digestive Oncology, University Hospitals Leuven, Leuven, Belgium.
  • Department of Radiology, University Hospital, LMU Munich, Munich, Germany; and.
  • Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
  • Nuclear Medicine, University Hospitals Leuven, and Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, University of Leuven, Leuven, Belgium; christophe.deroose@uzleuven.be.

Zitieren

APA

Leupe, H., Ahenkorah, S., Dekervel, J., Unterrainer, M., Van Cutsem, E., Verslype, C., Cleeren, F., & Deroose, C. M. (2023). 18 F-Labeled Somatostatin Analogs as PET Tracers for the Somatostatin Receptor: Ready for Clinical Use. Journal of Nuclear Medicine, 64(6), 835-841. https://doi.org/10.2967/jnumed.123.265622

Vancouver

Leupe H, Ahenkorah S, Dekervel J, Unterrainer M, Van Cutsem E, Verslype C, et al. 18 F-Labeled Somatostatin Analogs as PET Tracers for the Somatostatin Receptor: Ready for Clinical Use. Journal of Nuclear Medicine. 2023;64(6):835-841. doi:10.2967/jnumed.123.265622

BibTeX
@article{Leupe2023,
  author = {Leupe, Hannes and Ahenkorah, Stephen and Dekervel, Jeroen and Unterrainer, Marcus and Van Cutsem, Eric and Verslype, Chris and Cleeren, Frederik and Deroose, Christophe M},
  title = {18 F-Labeled Somatostatin Analogs as PET Tracers for the Somatostatin Receptor: Ready for Clinical Use},
  journal = {Journal of Nuclear Medicine},
  year = {2023},
  volume = {64},
  number = {6},
  pages = {835--841},
  doi = {10.2967/jnumed.123.265622}
}
Kostenlos starten →